Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of the 23 study patients who underwent exenteration

From: Pelvic exenteration in gynecologic cancer: complications and oncological outcome

Presentation of disease [n (%)]
 First diagnosis 2 (9)
 Relapse 19 (82)
 Persistence 2 (9)
Age [Mean ± SD (range)] 57.8  ± 12.4 (29–84)
BMI [Mean ± SD (range)] 27.4  ± 7.1 (17–50)
Menopausal status [n (%)]
 Pre 17 (74)
 Post 6 (26)
ECOG performance status [n (%)]
 0 20 (87)
 1 2 (9)
 2 1 (4)
Comorbidity [n (%)]
 None 15 (65)
 Hypertension 5 (22)
 Diabetes mellitus 5 (22)
 Hypercholesterolemia 1 (4)
 Monorenal 1 (4)
Primary tumour origin [n (%)]
 Vulvar cancer 9 (39)
 Cervix cancer 11 (48)
 Endometrial cancer 3 (13)
Previous treatment [n (%)]
 None 3 (13)
 RT 4 (17)
 ChT 0 (0)
 RT + ChT 16 (70)
Previous oncological surgery [n (%)]
 No 5 (22)
 Yes 18 (78)
ASA score [n (%)]
 1 1 (4)
 2 18 (78)
 3 4 (17)
Operative intention [n (%)]
 Curative 21 (91)
 Palliative 2 (9)
  1. BMI body mass index, ECOG Eastern Cooperative Oncology Group, RT radiotherapy, ChT chemotherapy, ASA operative risk assessed according to the American Society of Anaesthesiology score